Funding
BMEYE BV, a specialist in non-invasive cardiovascular monitoring, has announced the successful completion of its financing round – raising € 6 million. The round was led by Earlybird, with 360 Capital Partners and existing BMEYE shareholders Life Sciences Partners and Techfund.
BMEYE has begun selling Nexfin, an FDA and CE approved cardiovascular monitor that uses an easy-to-apply finger sensor to produce beat-to-beat, non-invasive blood pressure and cardiac output data, displayed on a touch screen. The new money will accelerate commercialisation.
“We are pleased to have completed this financing round, especially given today’s challenging economic climate” said Rob de Ree, BMEYE’s Chief Executive Officer. “This is a solid recognition of the quality of the BMEYE team and our success since the introduction of the Nexfin monitor.”
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
